Charlotte’s Web CBD Oil: Is It Effective Against Cancer?
Bethan Jenkins
September 18th, 2017
Policy
Cannabis comes in many forms, including bud, flower, edibles, concentrates and potent oil, like Charlotte’s Web CBD oil. You have most likely heard about this particular cultivar before, which has been hailed as a natural medication for treating seizures. According to the United States federal law, this type of medical cannabis is deemed to be a dietary supplement and is marketed in such a way.
Containing high levels of cannabidiol (CBD) and less than 0.3% tetrahydrocannabinol (THC), Charlotte’s Web is perhaps one of the most renowned cannabis extracts for its medical potential. It is thanks to the oil’s high-CBD content that it has been legally marketed for the promotion of mind and body wellness. Pure extracts of this kind have a CBD to THC ratio of 30:1 and since Charlotte’s Web is a non-psychoactive strain, there’s no wonder why the cultivar has gained popularity for patients of all ages.
Among the many medical conditions that this hemp whole-plant organic hemp extract oil has been scientifically proven to treat, Charlotte’s Web CBD oil has yet to be given the green light as a cancer cure. However, if you think hope is lost, it’s not.
The Story of Charlotte’s Web CBD Oil
Originating in Colorado, the Cannabis sativa strain was cultivated by Jesse and Joel Stanley, A.K.A. the Stanley Brothers. Claimed to be the “world’s most trusted hemp extract“, the naturally-crafted CBD oil was named after Charlotte Figi – a young girl who experienced relief from Dravet Syndrome instantly after consuming cannabis oil. Formerly confined to life in a wheelchair, Charlotte was struggling with as many as 300 seizures a week by age five, despite trying every medication possible.
It was when the young girl was aged six that she hit headlines for the first time, after her parents, Matt and Paige Figi, opted to administer their daughter with medical marijuana as a means of curing her rare form of epilepsy. Soon after reading positive testimonials pertaining to medical cannabis as a treatment for seizures, the Figi’s took a noble yet difficult step to obtain marijuana for their daughter. At this point, Charlotte could not eat, talk or walk properly. With the medication doing more harm than good, medical marijuana seemed to be the only option left.
Charlotte is now famous for becoming the youngest patient in her home state of Connecticut to apply for a medical marijuana card, of which was granted by Dr. Margaret Gedde. The results of using CBD oil were outstanding and Charlotte’s seizures stopped almost immediately after she began consuming the oil in her food twice daily. This led to the family seeking out help from the founders of the Realm of Caring Foundation – the Stanley Brothers. By means of crossbreeding a low-THC cannabis strain with industrial hemp, Charlotte’s Web was invented.
The Stanley Brothers Promote CBD Oil for Cancer Treatment
As the people responsible for the creation of Charlotte’s Web CBD oil, it goes without saying that the Stanley Brothers would advocate the oil as a miracle cure for a wide range of ailments. Something that really grasps people’s attention is the fact that the Stanley Brothers were brought up in an evangelical Christian family, yet they are undoubtedly two of today’s largest US cannabis oil producers.
Not only do the brothers promote Charlotte’s Web hemp for having anti-tumor properties (based on preclinical studies) but also, they encourage the general public to consider using high-CBD cannabis strains for the treatment of epilepsy, Alzheimer’s disease, Parkinson’s disease, depression, migraines, arthritis, PTSD, diabetes and interestingly, cancer. Described as “God’s plant” by the duo, Charlotte’s Web is now being considered a hopeful cure for cancer.
Cannabis as a Cancer Cure
So, it is being praised as a plant that can cure cancer, but how exactly does the evidence stack up? Well, cancer-stricken patients as young as seven years old (like Landon Riddle) have started taking control of their illness by using medical marijuana. Although the proof is currently restricted to anecdotal reports, cannabis is said to cause the death of cancer cells and for many patients suffering from leukemia, this is proving true.
Numerous undistinguished medical journals have published studies and reports related to using cannabis as a cancer cure and get this: Cannabidiol (CBD) is one of the marijuana plant’s 113 cannabinoids and, miraculously, evidence shows that leukemia cells are linked to cannabinoid receptors. When CBD attaches to the leukemia cells, they die. This means that CBD might just be the missing puzzle piece to cure cancer altogether.
Conclusion
Studies also show how CBD-rich cannabis extracts could effectively treat and cure colon cancer, which is another reason why Charlotte’s Web CBD oil is growing in popularity for medical purposes. While there is nothing set in stone to say that Charlotte’s Web CBD oil is effective against cancer quite yet, there is a lot to suggest that medical marijuana destroys cancer. Even the National Cancer Institute and the National Institute on Drug Abuse have confessed that cannabis does in fact shrink brain tumors and kill cancer cells.
To learn more about new cannabis medical devices and other news, sign-up for our free newsletter using the form to the right.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Bethan Jenkins
Bethan is a full-time wanderluster, traveler, and digital nomad with 7 years of experience in the freelance writing world. She has mastered the art of beating jet lag and using hammocks as an office for content curation.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
The Gluu is the first ever distribution platform serving the larger cannabis industry, linking together suppliers, manufacturers, reps, retailers and customers. If you sell products think of us as the B2B Amazon of the industry.
Valens GroWorks is a multi-licensed, vertically integrated provider of Canadian cannabis products with two wholly-owned subsidiaries located in Kelowna, BC.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
